about
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Novel mutant-selective EGFR kinase inhibitors against EGFR T790MCrizotinib in ALK-rearranged inflammatory myofibroblastic tumor.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencingA pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerImproving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitorDevelopment of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogeneBRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.A functional landscape of resistance to ALK inhibition in lung cancer.Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.MET and ALK as targets for the treatment of NSCLC.Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.Refractory pleural small cell carcinoma in never smoker. A case report.Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.Aromatase is differentially expressed in peripheral blood leukocytes from children, and adult female and male subjects.KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow nicheA breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genesDecreased androgen receptor gene methylation in premature pubarche: a novel pathogenetic mechanism?Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myelomaAmplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer
P50
Q27313799-D70D3E14-01C5-40C4-93B4-63AE6BDD2F17Q27658766-DB4267D6-4154-476C-A45E-1707C42B2FB9Q27851589-8B91D3C3-AAEF-4C62-B1BE-0F489F587CAFQ27851896-DD3A7CB1-1B26-486D-B39F-9592EA900FA9Q27852601-C9741803-F792-4549-B87B-882037131B94Q28275103-B6C1AF7A-5B5C-4A22-A734-CD8174E5F578Q30539299-C42DDB1A-CFC0-4791-B1DA-30196BB7BEEAQ33847889-BF3B6593-A0FA-4A99-92C0-0B299682641DQ34452854-588ABAA9-DB7E-4610-AC58-4ACC3719F50AQ34525925-4AEC35E2-6E5A-4CA2-A665-C75B9E32966FQ34593929-087A09D3-68A6-4B04-A389-B87CBDA95C64Q34606898-0760B54E-9423-4464-84AA-2209C1E96AD0Q35438912-E91C4BE5-F7C2-42EF-86C8-26F3B6E3F487Q36066539-B992627A-BE2A-4F12-BDCC-B2A28DBF009EQ37240662-033F12D6-F837-4B33-A81A-8CB346146ED1Q37455251-4A8E0474-BF4B-4F43-8DCE-CB4E0225D67FQ38153827-015182ED-4813-4908-AB6C-1FD461ECBD9BQ38429429-506DB1A7-3C53-4165-A38E-BF7DF18139C3Q38831440-0751830B-F5DF-4A7E-B10F-2BEB8851213DQ38852406-382235A5-5C94-4AE0-8306-7935BE3A09E6Q40001571-F6CE95B9-5C2D-4C21-A86F-3CB4FB26746DQ42826571-B01035ED-0410-41F8-BCEA-9EDC377C2ED7Q43883612-5AA58948-E49F-4090-8246-769824AC1FAAQ45994198-AC620E5A-9E4E-4AB0-ACCE-7FF09EA36842Q46338099-F5F03D3C-8378-4500-BBF2-D5063AC2A764Q46427909-4ADEEECF-C36B-4A6B-A07D-373A9AF8A38CQ46926668-C4453DBA-B52D-4FF9-94ED-35E9813EE273Q46960661-E53E9A59-CFB0-480E-A45A-32801F87C42FQ48536430-CE022CD0-2128-4D03-BD0D-EA224C93A706Q55312090-1E6D47A0-8FD9-45EE-8353-AA6809B892D7Q61640829-A94FD630-E251-43D1-AC6D-95C11F9A5BAEQ81709792-5D99F3DB-B2A8-4633-A66A-9BA157AE345FQ82223982-9B92453B-3755-45C3-A0B0-4F5E51470D42Q90351147-06E0A81B-0DD8-4B48-B956-F5F5C90F6132Q90722288-62B3BDA5-B937-4F21-AAB7-A2777D3A3B1C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marzia Capelletti
@ast
Marzia Capelletti
@en
Marzia Capelletti
@es
Marzia Capelletti
@nl
type
label
Marzia Capelletti
@ast
Marzia Capelletti
@en
Marzia Capelletti
@es
Marzia Capelletti
@nl
prefLabel
Marzia Capelletti
@ast
Marzia Capelletti
@en
Marzia Capelletti
@es
Marzia Capelletti
@nl
P106
P31
P496
0000-0001-5095-7060